Rapid symptom relief in rhinitis

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 1, 1999, Pages 25-29

  Bousquet, Jean ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Mizolastine; Perennial allergic rhinitis; Seasonal allergic rhinitis

Indexed keywords

CETIRIZINE; MIZOLASTINE;

ALLERGIC RHINITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

BENZIMIDAZOLES; DOUBLE-BLIND METHOD; HISTAMINE H1 ANTAGONISTS; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TIME FACTORS;

EID: 0032967484     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Dale H, Laidlaw P. The physiological action of β-imidazolethilamine. J Physiol (London) 1910; 41:318-44.
2. Ash A, Schild H. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27:427-39.
3. Black W, Dunian W, Durant C, Ganellin C, Parsons E. Definition and antagonism of histamine H2 receptors. Nature 1972; 236:385-90.
4. Arrang J, Garbarg M, Lancelot J, Lecomte J, Schwartz J. Highly potent and selective ligands for histamine H3 receptors. Nature 1987; 327:117-23.
5. Staub A, Bovet D. Actions de la thymoethyl-diethylamine (929F) et des éthers phénoliques sur le choc anaphylactique du cobaye. CR Soc Biol 1937; 128:818-25.
6. Halpern B. Les antihistaminiques de synthèse: essai de chimiothérapie des états allergiques. Arch Int Pharmacodyn Ther 1942; 68:339-45.
7. Niimi N, Noso N, Yamamoto S. The effect of histamine on cultured endothelial cells. A study of the mechanism of increased vascular permeability. Eur J Pharmacol 1992; 221:325-31.
8. Cheng HC, Woodward JK. A kinetic study of the antihistaminic effect of terfenadine. Arzneimittelforschung 1982; 32:1160-6.
9. Bousquet J, Campbell A, Michel F. Antilallergic activities of antihistamines. In: Therapeutic Index of Antihistamines. Church M, Rihoux J, ed. Lewinston, New York: Hogrefe & Huber, 1992: 57-95.
10. Bousquet J, Campbell A, Canonica G. H1-receptor antagonists: structure and classification. In: Simons F, ed. Histamine and H1-Receptor Antagonists in Allergic Disease. New York: Marcel Dekker Inc, 1996: 91-116.
11. Simons FE, Watson WT, Simons KJ. Lack of subsensitivity to terfenadine during long-term terfenadine treatment. J Allergy Clin Immunol 1988; 82:1068-75.
12. Bousquet J, Chanal I, Skassa-Brociek W, Lemonier C, Michel FB. Lack of subsensitivity to loratadine during long-term dosing during 12 weeks. J Allergy Clin Immunol 1990; 86:248-53.
13. Bousquet J, Vignola AM, Campbell AM, Michel FB. Pathophysiology of allergic rhinitis. Int Arch Allergy Immunol 1996; 110:207-18.
14. International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy 1994; 49:1-34.
15. Rosenzweig P, Thebault JJ, Caplain H, et al. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy 1992; 69:135-9.
16. Levrier J, Duval D, Prouteau M, et al. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. Arzneimittelforschung 1995; 45:559-68.
17. Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimiltelforschung 1998; 48:173-8.
18. Danjou P, Molinier P, Berlin I, Patat A, Rosenzweig P, Morselli PL. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol 1992; 34:328-31.
19. Bousquet J, Chanal I, Murrieta M, Stalla-Bourdillon A. Lack of subsensitivity to mizolastine over 8-weeks treatment. Allergy 1996; 51:251-6.
20. Depoortere H, Decobert M, Granger P, Francon D. Mizolastine, a novel selective histamine H1 receptor antagonist: lack of sedative potential on the EEG in the rodent. Neuropsychobiology 1995; 32:214-21.
21. Kerr JS, Dunmore C, Hindmarch I. The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers. Eur J Clin Pharmacol 1994; 47:331-5.
22. Vuurman EF, Uiterwijk MM, Rosenzweig P, O'Hanlon JF. Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 1994; 47:253-9.
23. Patat A, Stubbs D, Dunmore C, et al. Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 1995; 48:143-50.
24. Leynadier F, Bousquet J, Murrieta M, Attali P. Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann Allergy Asthma Immunol 1996; 76:163-8.
25. Stern MA, Darnell R, Tudor D. Can an antihistamine delay appearance of hay fever symptoms when given prior to pollen season? Allergy 1997; 52:440-4.
26. Bellioni P, Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A. Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996; 34:101-4.
27. Daele J, Sabbah A, Wade AG, Bensoussen P, Attali P. Onset of action mizolastine 10mg OD in the treatment of seasonal allergic rhinoconjunctivitis (SAR) comparatively to cetirizine 10mg od and placebo. Allergy 1998; 53(Suppl. 43) abstr P 421.
28. Bachert C, Brostoff J, Scadding G, Tasman J, Stalla-Bourdillon A, Murrieta M. and the Riperan Study Group. Mizolastine therapy has also an effect on nasal blockade in perennial allergic rhinoconjunctivitis. Allergy 1998; 53:969-75.